tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Can-Fite BioPharma Announces June 2025 Shareholder Meeting
PremiumCompany AnnouncementsCan-Fite BioPharma Announces June 2025 Shareholder Meeting
2M ago
Can-Fite BioPharma Secures $175 Million for Phase III Trials
Premium
Company Announcements
Can-Fite BioPharma Secures $175 Million for Phase III Trials
3M ago
Can-Fite raises $175M to date for namodenoson, piclidenoson development
Premium
The Fly
Can-Fite raises $175M to date for namodenoson, piclidenoson development
3M ago
Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
PremiumThe FlyCan-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
3M ago
Can-Fite BioPharma Reports 2024 Financial Results and Clinical Progress
Premium
Company Announcements
Can-Fite BioPharma Reports 2024 Financial Results and Clinical Progress
3M ago
Can-Fite BioPharma Secures $3 Million in Direct Offering
Premium
Company Announcements
Can-Fite BioPharma Secures $3 Million in Direct Offering
3M ago
Can-Fite BioPharma announces completion of analysis of current partnerships
PremiumThe FlyCan-Fite BioPharma announces completion of analysis of current partnerships
3M ago
Can-Fite BioPharma Reports 2024 Financial Results and Clinical Advances
Premium
Company Announcements
Can-Fite BioPharma Reports 2024 Financial Results and Clinical Advances
3M ago
Can-Fite BioPharma reports FY24 EPS 0c vs 1c last year
Premium
The Fly
Can-Fite BioPharma reports FY24 EPS 0c vs 1c last year
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100